Hoba Pharmaceutical Holdings Limited (Hoba Pharma-B) submitted its next day disclosure report on September 16, 2024, disclosing its shareholding changes. The report shows that Hoba Pharmaceutical repurchased 350,000 ordinary shares on September 16, 2024, accounting for 0.0455% of its issued shares. The repurchase price range was HKD 1.11 to HKD 1.19 per share, with a total payment of HKD 404,160. The repurchased shares will be held as treasury shares. The company confirms that this repurchase action has been approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. In addition, Hoba Pharmaceutical obtained repurchase authorization on June 6, 2024, with a total number of shares that can be repurchased of 76,887,641 shares, and currently 550,000 shares have been repurchased. The suspension period after the repurchase will continue until October 16, 2024.

Hoba Pharmaceutical Holdings Limited (Hoba Pharma-B) submitted its next day disclosure report on September 16, 2024, disclosing its shareholding changes. The report shows that Hoba Pharmaceutical repurchased 350,000 ordinary shares on September 16, 2024, accounting for 0.0455% of its issued shares. The repurchase price range was HKD 1.11 to HKD 1.19 per share, with a total payment of HKD 404,160. The repurchased shares will be held as treasury shares. The company confirms that this repurchase action has been approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. In addition, Hoba Pharmaceutical obtained repurchase authorization on June 6, 2024, with a total number of shares that can be repurchased of 76,887,641 shares, and currently 550,000 shares have been repurchased. The suspension period after the repurchase will continue until October 16, 2024.